Fate Therapeutics Announces Executive Changes and Board Election
Ticker: FATE · Form: 8-K · Filed: Nov 29, 2024 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 8-K |
| Filed Date | Nov 29, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, board-election, personnel
TL;DR
Fate Therapeutics shakes up leadership: CMO out, new CMO and board member in. #biotech #execchanges
AI Summary
On November 27, 2024, Fate Therapeutics, Inc. announced the departure of Dr. Wayne V. Saville from his role as Chief Medical Officer. The company also reported the election of Dr. Nicole T. Williams as a new director and the appointment of Dr. Adam L. Rosenthal as Chief Medical Officer, effective November 27, 2024. Additionally, the company disclosed compensatory arrangements for its officers.
Why It Matters
This filing indicates significant leadership changes within Fate Therapeutics, including the appointment of a new Chief Medical Officer and a new board member, which could signal shifts in the company's strategic direction or operational focus.
Risk Assessment
Risk Level: medium — Changes in key executive positions and board composition can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Fate Therapeutics, Inc. (company) — Registrant
- Dr. Wayne V. Saville (person) — Departing Chief Medical Officer
- Dr. Nicole T. Williams (person) — Newly Elected Director
- Dr. Adam L. Rosenthal (person) — Newly Appointed Chief Medical Officer
- November 27, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Adam L. Rosenthal has been appointed as the new Chief Medical Officer, effective November 27, 2024.
Who has departed from their role as Chief Medical Officer?
Dr. Wayne V. Saville has departed from his role as Chief Medical Officer.
Who has been elected as a new director to the board?
Dr. Nicole T. Williams has been elected as a new director.
What is the effective date of these reported changes?
The earliest event reported is November 27, 2024.
What other information is disclosed in this 8-K filing?
The filing also includes information regarding compensatory arrangements of certain officers and Regulation FD disclosures.
Filing Stats: 852 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2024-11-29 14:33:53
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share FATE The Nasdaq
Filing Documents
- d816234d8k.htm (8-K) — 27KB
- d816234dex991.htm (EX-99.1) — 15KB
- g816234dsp1a.jpg (GRAPHIC) — 4KB
- 0001193125-24-268003.txt ( ) — 171KB
- fate-20241127.xsd (EX-101.SCH) — 3KB
- fate-20241127_lab.xml (EX-101.LAB) — 17KB
- fate-20241127_pre.xml (EX-101.PRE) — 11KB
- d816234d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated November 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 29, 2024 Fate Therapeutics, Inc. By: /s/ Cindy R. Tahl Cindy R. Tahl Chief Legal and Compliance Officer